Ferris, R. L., Even, C., Haddad, R., Tahara, M., Goswami, T., Franks, A., . . . Licitra, L. (2015). Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Eagle. J Immunother Cancer.
Citação norma ChicagoFerris, Robert L., et al. "Phase III, Randomized, Open-label Study of Durvalumab (MEDI4736) Monotherapy, or Durvalumab + Tremelimumab, Versus Standard of Care (SoC), in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Eagle." J Immunother Cancer 2015.
ציטוט MLAFerris, Robert L., et al. "Phase III, Randomized, Open-label Study of Durvalumab (MEDI4736) Monotherapy, or Durvalumab + Tremelimumab, Versus Standard of Care (SoC), in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Eagle." J Immunother Cancer 2015.